Related Experiment Video
Updated: Jul 30, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Driving-Related Glucose Monitoring Practices Among Insulin-Treated Adults With Type 2 Diabetes
Katharine Barnard-Kelly1,2, Ryan Charles Kelly2, Anthony Chen3
1BHR Limited, Fareham, UK.
Journal of Diabetes Science and Technology
|May 31, 2026
Summary
Many drivers with insulin-treated type 2 diabetes engage in unsafe behaviors, particularly concerning hypoglycemia. Improved education on safe driving practices is crucial for this population.
Area of Science:
- Endocrinology
- Neurology
- Public Health
Background:
- Diabetes mellitus, particularly type 2 diabetes (T2D), can impair cognitive, motor, and sensory functions essential for driving.
- Hypoglycemia is a significant safety concern for individuals with T2D requiring insulin therapy.
- Existing guidance for insulin-treated drivers may not be adequately understood or followed.
Purpose of the Study:
- To assess driving behaviors and safety concerns among individuals with insulin-treated T2D.
- To evaluate adherence to safe driving recommendations related to glucose monitoring and hypoglycemia management.
- To identify potential gaps in understanding or implementing safe driving practices.
Main Methods:
- An online survey was administered to 500 licensed drivers with insulin-requiring T2D in the US and UK, excluding continuous glucose monitoring (CGM) users.
- The survey collected data on diabetes management, driving habits, and concerns regarding hypoglycemia.
- Descriptive and inferential statistical analyses were employed to interpret the survey data.
Main Results:
- 34% of participants reported severe hypoglycemia in the past year, and 54% showed impaired awareness of hypoglycemia.
- 37% limited driving due to insulin concerns, with 72% specifically worried about hypoglycemia.
- Only 34% regularly checked glucose before driving, and many exhibited risky behaviors when experiencing or anticipating hypoglycemia.
Conclusions:
- A significant proportion of insulin-treated T2D drivers engage in potentially unsafe driving behaviors.
- There is a clear need for enhanced education and understanding of guidelines for safe driving among individuals with insulin-treated T2D.
- Addressing hypoglycemia concerns and improving glucose monitoring practices are critical for driver safety.
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:15Diabetes: Symptoms, Diagnosis, and Complications
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...